[go: up one dir, main page]

WO2002008399A3 - Kinases humaines - Google Patents

Kinases humaines Download PDF

Info

Publication number
WO2002008399A3
WO2002008399A3 PCT/US2001/023092 US0123092W WO0208399A3 WO 2002008399 A3 WO2002008399 A3 WO 2002008399A3 US 0123092 W US0123092 W US 0123092W WO 0208399 A3 WO0208399 A3 WO 0208399A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkin
provides
human kinases
human
kinases
Prior art date
Application number
PCT/US2001/023092
Other languages
English (en)
Other versions
WO2002008399A2 (fr
Inventor
Henry Yue
Farrah A Khan
Rajagopal Gururajan
April J A Hafalia
Naribder K Chawla
Chandra S Arvizu
Original Assignee
Incyte Genomics Inc
Henry Yue
Farrah A Khan
Rajagopal Gururajan
April J A Hafalia
Naribder K Chawla
Chandra S Arvizu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Henry Yue, Farrah A Khan, Rajagopal Gururajan, April J A Hafalia, Naribder K Chawla, Chandra S Arvizu filed Critical Incyte Genomics Inc
Priority to US10/333,314 priority Critical patent/US20030211093A1/en
Priority to AU2001277959A priority patent/AU2001277959A1/en
Priority to EP01955908A priority patent/EP1356032A2/fr
Priority to CA002416414A priority patent/CA2416414A1/fr
Priority to JP2002513883A priority patent/JP2004527209A/ja
Publication of WO2002008399A2 publication Critical patent/WO2002008399A2/fr
Publication of WO2002008399A3 publication Critical patent/WO2002008399A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des kinases humaines (PKIN) et des polynucléotides identifiant et codant PKIN. Elle concerne également des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. Elle concerne également des procédés servant à diagnostiquer, traiter ou prévenir des troubles associés à l'expression aberrante de PKIN.
PCT/US2001/023092 2000-07-21 2001-07-20 Kinases humaines WO2002008399A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/333,314 US20030211093A1 (en) 2001-07-20 2001-07-20 Human kinases
AU2001277959A AU2001277959A1 (en) 2000-07-21 2001-07-20 Human kinases
EP01955908A EP1356032A2 (fr) 2000-07-21 2001-07-20 Kinases humaines
CA002416414A CA2416414A1 (fr) 2000-07-21 2001-07-20 Kinases humaines
JP2002513883A JP2004527209A (ja) 2000-07-21 2001-07-20 ヒトキナーゼ

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22003800P 2000-07-21 2000-07-21
US60/220,038 2000-07-21
US22211200P 2000-07-28 2000-07-28
US60/222,112 2000-07-28
US22283100P 2000-08-04 2000-08-04
US60/222,831 2000-08-04
US22472900P 2000-08-11 2000-08-11
US60/224,729 2000-08-11

Publications (2)

Publication Number Publication Date
WO2002008399A2 WO2002008399A2 (fr) 2002-01-31
WO2002008399A3 true WO2002008399A3 (fr) 2003-08-28

Family

ID=27499171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023092 WO2002008399A2 (fr) 2000-07-21 2001-07-20 Kinases humaines

Country Status (5)

Country Link
EP (1) EP1356032A2 (fr)
JP (1) JP2004527209A (fr)
AU (1) AU2001277959A1 (fr)
CA (1) CA2416414A1 (fr)
WO (1) WO2002008399A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1484408A1 (fr) * 1999-09-28 2004-12-08 Lexicon Genetics Incorporated Proteines de kinase de l'homme et polynucleotides codant ces dernieres
WO2001079488A2 (fr) * 2000-04-13 2001-10-25 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteine kinase, 14257, et leurs utilisations
US7094587B2 (en) 2000-06-27 2006-08-22 Millennium Pharmaceuticals, Inc. 16002 Molecules and uses therefor
AU2001279106A1 (en) * 2000-07-28 2002-02-13 Chiron Corporation Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides
WO2002020754A2 (fr) * 2000-09-05 2002-03-14 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
WO2003023034A2 (fr) * 2001-09-12 2003-03-20 Bayer Healthcare Ag Regulation de tau-tubuline kinase humaine
CA2478118A1 (fr) * 2002-03-05 2003-09-18 Applera Corporation Proteines kinases humaines isolees, molecules d'acides nucleiques codant des proteines kinases humaines, et leurs utilisations
AU2003221030A1 (en) * 2002-04-05 2003-10-20 K. K. Dnaform Novel proteins and dnas encoding the same
JP2003289876A (ja) * 2002-04-05 2003-10-14 Takeda Chem Ind Ltd がんの予防および／または治療剤
EP1507856A1 (fr) * 2002-05-15 2005-02-23 Bayer HealthCare AG Regulation de la serine/threonine kinase humaine
EP1575518A4 (fr) 2002-10-10 2007-08-22 Wyeth Corp Compositions, organismes et methodologies utilisant une nouvelle kinase humaine
EP1554385A2 (fr) 2002-10-24 2005-07-20 Wyeth Compositions, organismes et procedes faisant appel a une nouvelle proteine phosphatase humaine
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
WO2004050831A2 (fr) * 2002-11-27 2004-06-17 Wyeth Compositions, organismes et procedes faisant appel a une nouvelle kinase humaine
JP2006520605A (ja) * 2003-03-20 2006-09-14 メタボレックス インコーポレーティッド ヘキソキナーゼｖを用いる組成物および方法
WO2004087903A2 (fr) * 2003-03-28 2004-10-14 Wyeth Proteines homologues du kinase suppresseur de ras
US20050125852A1 (en) * 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014212A1 (fr) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteine kinase et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014212A1 (fr) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteine kinase et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] "insulin receptor-related receptor", XP002213066, Database accession no. p14616 *
HAENZE J ET AL: "CLONING AND SEQUENCING OF THE COMPLETE CDNA ENCODING THE HUMAN INSULIN RECEPTOR RELATED RECEPTOR", HORMONE AND METABOLIC RESEARCH, THIEME-STRATTON, STUTTGART, DE, vol. 31, no. 2/3, 1999, pages 77 - 79, XP000944669, ISSN: 0018-5043 *
SCHULTZ S J ET AL: "IDENTIFICATION OF 21 NOVEL HUMAN PROTEIN KINASES, INCLUDING 3 MEMBERS OF A FAMILY RELATED TO THE CELL CYCLE REGULATOR NIMA OF ASPERGILLUS NIDULANS", CELL GROWTH AND DIFFERENTIATION, THE ASSOCIATION, PHILADELPHIA, PA, US, vol. 4, 1 October 1993 (1993-10-01), pages 821 - 830, XP000564042, ISSN: 1044-9523 *
SHIER P AND WATT V M: "Primary structure of a putative receptor for a ligand of the insulin family", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 264, no. 25, P14616, 5 September 1989 (1989-09-05), pages 14605 - 14608, XP002154780, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
JP2004527209A (ja) 2004-09-09
AU2001277959A1 (en) 2002-02-05
EP1356032A2 (fr) 2003-10-29
CA2416414A1 (fr) 2002-01-31
WO2002008399A2 (fr) 2002-01-31

Similar Documents

Publication Publication Date Title
WO2001098468A3 (fr) Proteases
WO2002008399A3 (fr) Kinases humaines
WO2002018557A3 (fr) Kinases humaines
WO2001096547A3 (fr) Kinases humaines
WO2001060991A3 (fr) Kinases humaines
WO2002008396A3 (fr) Proteases
WO2003033680A3 (fr) Kinases et phosphatases
WO2001010903A3 (fr) Proteases et inhibiteurs de proteases
WO2001051638A3 (fr) Enzymes de metabolisation de medicaments
WO2002046384A3 (fr) Kinases et phosphatases
WO2002083709A3 (fr) Kinases et phosphatases
WO2001046397A3 (fr) Kinases humaines
WO2001090334A3 (fr) Enzymes de metabolisation de medicaments
WO2001072777A3 (fr) Facteurs de transcription
WO2000000594A3 (fr) Transferases humaines
WO2002004612A3 (fr) Enzymes metabolisant les medicaments
WO2002038744A3 (fr) Protéases
WO2001071004A3 (fr) Proteases
WO2001098471A8 (fr) Phosphodiesterases
WO2000015770A3 (fr) Serine/threonine proteines-kinases
WO2002026950A3 (fr) Transferases
WO2001081555A3 (fr) Kinases humaines
WO2000042201A3 (fr) Peptidases humaines
WO2002033099A3 (fr) Kinases humaines
WO2001079468A3 (fr) Enzymes metabolisant les medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10333314

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2416414

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001955908

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2001955908

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003133305

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 2001955908

Country of ref document: EP